83 related articles for article (PubMed ID: 16373886)
21. Mutations in bone morphogenetic protein type II receptor cause dysregulation of Id gene expression in pulmonary artery smooth muscle cells: implications for familial pulmonary arterial hypertension.
Yang J; Davies RJ; Southwood M; Long L; Yang X; Sobolewski A; Upton PD; Trembath RC; Morrell NW
Circ Res; 2008 May; 102(10):1212-21. PubMed ID: 18436795
[TBL] [Abstract][Full Text] [Related]
22. [BMP receptors and signal transduction].
Hayashi M; Imamura T; Miyazono K
Nihon Rinsho; 2005 Oct; 63 Suppl 10():399-403. PubMed ID: 16279670
[No Abstract] [Full Text] [Related]
23. [Analysis of transgenic and knockout mice for BMP receptors].
Tsuchida K; Nakatani M
Nihon Rinsho; 2005 Oct; 63 Suppl 10():418-21. PubMed ID: 16279674
[No Abstract] [Full Text] [Related]
24. Molecular pathogenesis of pulmonary arterial hypertension.
Rabinovitch M
J Clin Invest; 2008 Jul; 118(7):2372-9. PubMed ID: 18596905
[TBL] [Abstract][Full Text] [Related]
25. Loss of bone morphogenetic protein receptor 2 is associated with abnormal DNA repair in pulmonary arterial hypertension.
Li M; Vattulainen S; Aho J; Orcholski M; Rojas V; Yuan K; Helenius M; Taimen P; Myllykangas S; De Jesus Perez V; Koskenvuo JW; Alastalo TP
Am J Respir Cell Mol Biol; 2014 Jun; 50(6):1118-28. PubMed ID: 24433082
[TBL] [Abstract][Full Text] [Related]
26. Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension.
Yang X; Long L; Southwood M; Rudarakanchana N; Upton PD; Jeffery TK; Atkinson C; Chen H; Trembath RC; Morrell NW
Circ Res; 2005 May; 96(10):1053-63. PubMed ID: 15845886
[TBL] [Abstract][Full Text] [Related]
27. The mouse through the looking glass: a new door into the pathophysiology of pulmonary hypertension.
Rabinovitch M
Circ Res; 2004 Apr; 94(8):1001-4. PubMed ID: 15117827
[No Abstract] [Full Text] [Related]
28. Interaction between bone morphogenetic proteins and endothelin-1 in human pulmonary artery smooth muscle.
Din S; Sarathchandra P; Yacoub MH; Chester AH
Vascul Pharmacol; 2009; 51(5-6):344-9. PubMed ID: 19786120
[TBL] [Abstract][Full Text] [Related]
29. Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle.
West J; Fagan K; Steudel W; Fouty B; Lane K; Harral J; Hoedt-Miller M; Tada Y; Ozimek J; Tuder R; Rodman DM
Circ Res; 2004 Apr; 94(8):1109-14. PubMed ID: 15031260
[TBL] [Abstract][Full Text] [Related]
30. Increased pericyte coverage mediated by endothelial-derived fibroblast growth factor-2 and interleukin-6 is a source of smooth muscle-like cells in pulmonary hypertension.
Ricard N; Tu L; Le Hiress M; Huertas A; Phan C; Thuillet R; Sattler C; Fadel E; Seferian A; Montani D; Dorfmüller P; Humbert M; Guignabert C
Circulation; 2014 Apr; 129(15):1586-97. PubMed ID: 24481949
[TBL] [Abstract][Full Text] [Related]
31. Receptor for activated C-kinase 1, a novel interaction partner of type II bone morphogenetic protein receptor, regulates smooth muscle cell proliferation in pulmonary arterial hypertension.
Zakrzewicz A; Hecker M; Marsh LM; Kwapiszewska G; Nejman B; Long L; Seeger W; Schermuly RT; Morrell NW; Morty RE; Eickelberg O
Circulation; 2007 Jun; 115(23):2957-68. PubMed ID: 17515463
[TBL] [Abstract][Full Text] [Related]
32. Involvement of BMPR2 in the protective effect of fluoxetine against monocrotaline-induced endothelial apoptosis in rats.
Wang Y; Zhang XH; Wang HL
Can J Physiol Pharmacol; 2011 May; 89(5):345-54. PubMed ID: 21619414
[TBL] [Abstract][Full Text] [Related]
33. Gut-Lung Connection in Pulmonary Arterial Hypertension.
Ranchoux B; Bigorgne A; Hautefort A; Girerd B; Sitbon O; Montani D; Humbert M; Tcherakian C; Perros F
Am J Respir Cell Mol Biol; 2017 Mar; 56(3):402-405. PubMed ID: 28248132
[No Abstract] [Full Text] [Related]
34. The imitation game in pulmonary arterial hypertension. Sex, bone morphogenetic protein receptor, and the estrogen paradox.
Singla S; Machado RF
Am J Respir Crit Care Med; 2015 Mar; 191(6):612-3. PubMed ID: 25767922
[No Abstract] [Full Text] [Related]
35. Bone morphogenetic protein receptor type II and inflammation are bringing old concepts into the new pulmonary arterial hypertension world.
Perros F; Bonnet S
Am J Respir Crit Care Med; 2015 Oct; 192(7):777-9. PubMed ID: 26426782
[No Abstract] [Full Text] [Related]
36. Chloroquine in pulmonary arterial hypertension: a new role for an old drug?
Ryan JJ
Circ Cardiovasc Genet; 2013 Jun; 6(3):310-1. PubMed ID: 23778591
[No Abstract] [Full Text] [Related]
37. Hungry for more: autophagy in the pathogenesis of pulmonary arterial hypertension.
Fraidenburg DR; Yuan JX
Circ Res; 2013 Apr; 112(8):1091-3. PubMed ID: 23580770
[No Abstract] [Full Text] [Related]
38. Pulmonary hypertension: cellular and molecular mechanisms.
Cool CD; Groshong SD; Oakey J; Voelkel NF
Chest; 2005 Dec; 128(6 Suppl):565S-571S. PubMed ID: 16373828
[No Abstract] [Full Text] [Related]
39. Cell-based therapies in pulmonary hypertension: who, what, and when?
Majka S; Burnham E; Stenmark KR
Am J Physiol Lung Cell Mol Physiol; 2011 Jul; 301(1):L9-L11. PubMed ID: 21515661
[No Abstract] [Full Text] [Related]
40. Emerging concepts and translational priorities in pulmonary arterial hypertension.
Michelakis ED; Wilkins MR; Rabinovitch M
Circulation; 2008 Sep; 118(14):1486-95. PubMed ID: 18824655
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
